Global Enteric Disease Testing Market to Garner Brimming Revenues by 2017 - 2025

Researchmoz added Most up-to-date research on "Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025" to its huge collection of research reports. An insight on the important factors and trends influencing the market.

Global Enteric Disease Testing Market: Overview
This report on enteric disease testing market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing test kits for enteric disease testing as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global enteric disease testing market with respect to the leading market segments based on disease indication, testing methods, end-user, and geographies.
Request Free Sample Pages Of This Premium Research Report: https://www.researchmoz.us/enquiry.php?type=S&repid=170120
Global Enteric Disease Testing Market: Segmentation
Based on disease indication, the enteric disease testing market has been majorly segmented into: bacterial enteric disease, viral enteric disease, and parasitic enteric disease. Bacterial enteric disease includes segments such as C.difficile Infection, campylobacteriosis, cholera, E.coli infection, H.pylori infection, salmonellosis, and shigellosis. Viral enteric disease includes rotavirus infection and norovirus infection. Parasitic enteric disease includes amebiasis, cryptosporidiosis and giardiasis. In terms of testing methods, the enteric disease testing market has been broadly classified into immunoassay testing, conventional testing, and molecular diagnostic testing. In terms of end-users, the enteric disease testing market has been broadly classified into hospitals, diagnostic laboratories, and physician offices.
Global Enteric Disease Testing Market: Research Methodology
Each of the market segments have been extensively analyzed based on the market related factors such as incidence and prevalence of enteric bacterial infection and rise in application of molecular diagnostics for enteric disease testing. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the enteric disease testing market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global enteric disease testing market.
Global Enteric Disease Testing Market: Geographical and Competitive Dynamics
Geographically, enteric disease testing market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides with market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, porter’s five forces analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global enteric disease testing market.
The key findings section included in the report would assist existing market players in expanding their market shares, and new companies in establishing their presence in the global enteric disease testing market. The report also profiles key players operating in the enteric disease testing market which are Trinity Biotech plc, Biomerica, Inc., Bio-Rad Laboratories, Inc., Alere Inc., Biomerieux SA, Meridian Bioscience Inc., CorisBioconcept SPRL, Quest Diagnostics Incorporated, Cepheid Inc., DiaSorin and other prominent companies.
The global enteric disease testing market is segmented as follows:
Global Enteric Disease Testing Market, by Disease Indication
- Bacterial Enteric Disease
- C.difficile Infection
- Campylobacteriosis
- Cholera
- E.coli Infection
- H.pylori Infection
- Salmonellosis
- Shigellosis
- Viral Enteric Disease
- Rotavirus Infection
- Norovirus Infection
- Parasitic Enteric Disease
- Amebiasis
- Cryptosporidiosis
- Giardiasis
Contact For Discount or to Get Customized Report: https://www.researchmoz.us/enquiry.php?type=E&repid=170120
Global Enteric Disease Testing Market, by Testing Methods
- Immunoassay Testing
- Conventional Testing
- Molecular Diagnostic Testing
Global Enteric Disease Testing Market, by End-user
- Hospitals
- Diagnostic Laboratories
- Physician Offices
Global Enteric Disease Testing Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- U.K.
- Rest of Europe
- Asia Pacific
- India
- Japan
- China
- Australia & New Zealand
- Rest of Asia
- Latin America (LATAM)
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

Researchmoz added Most up-to-date research on "Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa" to its huge collection of research reports. An insight on the important factors and trends influencing the market.
Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases.
Get Free PDF for More Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1918257
Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and rare dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors.
Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across orphan and rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.
This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key indications, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa (EB), pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus (CLE), as these conditions have the largest pipelines within the therapy area.
Scope
- There is a strong need for innovative new therapies across the orphan and rare dermatology market. How are orphan and rare dermatological diseases currently managed? What are the greatest unmet needs within this market?
- There are 262 pipeline products in development across all orphan and rare dermatological diseases. How does the composition of the pipeline compare with that of the existing market? Which molecular targets are most frequently acted upon by pipeline drugs? How do products in development for the key indications differ in terms of molecule type?
- Over one-third of pipeline products with a disclosed molecular target are first-in-class. How does the proportion of first-in-class products in development differ in terms of stage of development, molecule type and molecular target class? Which are the most promising first-in-class targets?
- The deals landscape has become more active in recent years. Which indications and products have attracted the highest deal values?
Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=1918257
Reasons to buy
This report will allow you to:
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Visualize the composition of the market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix, first-in-class targets have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

Researchmoz added latest report "Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.
Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases.

Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and rare dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1918257

Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across orphan and rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key indications, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa (EB), pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus (CLE), as these conditions have the largest pipelines within the therapy area.

Scope

- There is a strong need for innovative new therapies across the orphan and rare dermatology market. How are orphan and rare dermatological diseases currently managed? What are the greatest unmet needs within this market?
- There are 262 pipeline products in development across all orphan and rare dermatological diseases. How does the composition of the pipeline compare with that of the existing market? Which molecular targets are most frequently acted upon by pipeline drugs? How do products in development for the key indications differ in terms of molecule type?
- Over one-third of pipeline products with a disclosed molecular target are first-in-class. How does the proportion of first-in-class products in development differ in terms of stage of development, molecule type and molecular target class? Which are the most promising first-in-class targets?
- The deals landscape has become more active in recent years. Which indications and products have attracted the highest deal values?

Reasons to buy

This report will allow you to:
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Visualize the composition of the market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix, first-in-class targets have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/frontier-pharma-orphan-and-rare-dermatological-diseases-firstinclass-therapies-demonstrate-potential-diseasemodifying-effects-in-areas-of-high-unmet-need-such-as-epidermolysis-bullosa-report.html/toc

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

ResearchMoz presents detailed study of "Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products". The report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the Track and Trace Solutions Market.
Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure, and is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the patent’s history of alcohol use.

FLD is the most common chronic liver disease in the world, and its global prevalence has increased rapidly in the past several decades. The worldwide prevalence of FLD is estimated at 20–45% in the general population, and up to 90% in obese patients. There is a broad consensus to describe the condition as the hepatic manifestation of metabolic syndrome, and it is closely associated with obesity, diabetes and dyslipidemia. NAFLD has become the main driver of the rapid growth of FLD prevalence, mainly due to the rising prevalence of obesity.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1065937

FLD is increasingly recognized as a major global health problem. However, despite this the FLD market is still in its infancy, with no FDA-approved drugs for this indication, and only a limited number of generic drugs approved in non-US markets in recent years.

Due to the increasing health burden of FLD and the lack of therapeutic options, there is a pressing need to develop pharmacological strategies. This is especially the case for patients with steatohepatitis, who are at the greatest risk of developing cirrhosis or liver cancer, which can lead to liver failure. Due to the pathophysiological complexity of FLD and its diverse population, different therapeutic agents are likely to be needed to tackle the lipotoxicity, inflammation and fibrogenesis that drive FLD progression.

FLD has an active pipeline and first-in-class products account for a considerable proportion, which is very promising considering the level of unmet need and lack of approved treatment options. First-in-class innovation is concentrated heavily at the early drug development stages, and prominent first-in-class molecular targets include nuclear receptors, immune mediators, and molecules involved in lipid synthesis. Additionally, the first-in-class targets identified show considerable diversity, reflecting the multifaceted aspects of FLD pathophysiology.

Scope

FLD comprises a diverse patient population with significant unmet needs
- What is the pathophysiology of FLD?
- What are the common co-morbidities and complications?
- What are the most significant unmet needs within the market?

The FLD pipeline is relatively large and has a high degree of first-in-class innovation

- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The FLD deal landscape shows rising deal volumes and considerable investment opportunities

- Do FLD products attract high deal values?
- Which molecule types and molecular targets dominate the deals landscape?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/frontier-pharma-fatty-liver-disease-high-degree-of-firstinclass-innovation-dominated-by-nuclear-receptortargeting-nash-products-report.html/toc

Reasons to buy

This report will allow you to - 
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.
- Visualize the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to FLD, all first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

Researchmoz added latest report "Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.
Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases.

Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and rare dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1918257

Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across orphan and rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key indications, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa (EB), pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus (CLE), as these conditions have the largest pipelines within the therapy area.

Scope

- There is a strong need for innovative new therapies across the orphan and rare dermatology market. How are orphan and rare dermatological diseases currently managed? What are the greatest unmet needs within this market?
- There are 262 pipeline products in development across all orphan and rare dermatological diseases. How does the composition of the pipeline compare with that of the existing market? Which molecular targets are most frequently acted upon by pipeline drugs? How do products in development for the key indications differ in terms of molecule type?
- Over one-third of pipeline products with a disclosed molecular target are first-in-class. How does the proportion of first-in-class products in development differ in terms of stage of development, molecule type and molecular target class? Which are the most promising first-in-class targets?
- The deals landscape has become more active in recent years. Which indications and products have attracted the highest deal values?

Reasons to buy

This report will allow you to:
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Visualize the composition of the market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix, first-in-class targets have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/frontier-pharma-orphan-and-rare-dermatological-diseases-firstinclass-therapies-demonstrate-potential-diseasemodifying-effects-in-areas-of-high-unmet-need-such-as-epidermolysis-bullosa-report.html/toc

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Global Orphan Drugs Market To Grow At A CAGR Of 10.20% During The Period 2017-2021 – AbbVie, Celgene, F. Hoffmann La Roche, Novartis

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market 2017-2021" to its huge collection of research reports.

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.

Get PDF for More Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1059719

Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Celgene
F. Hoffmann La Roche
Novartis

Other prominent vendors
Amgen
Actelion
Alexion Pharmaceuticals
Bayer
Biogen
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Novo Nordisk
Pfizer
Sanofi
Shire
Teva pharmaceutical

Market driver
Large growth opportunities through orphan drug designation.
For a full, detailed list, view our report

Market challenge
Costly treatment regimen results in financial burden on patients.
For a full, detailed list, view our report

Market trend
Emerging application for orphan drug development.
For a full, detailed list, view our report

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-orphan-drugs-market-2017-2021-report.html/toc

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Crohns Disease Market: Global Industry Analysis and Forecast, 2016-2024 | Allergan, Inc., UCB S.A., AbbVie Inc., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, Ferring B.V.

Researchmoz added Most up-to-date research on "Global Market Study on Crohns Disease: Anti-inflammatory Drugs Segment Anticipated to be the Most Lucrative Segment Through 2024" to its huge collection of research reports.

In its recently published report titled Crohns Disease Market: Global Industry Analysis and Forecast, 2016-2024, Persistence Market Research presents an outlook of the global Crohns disease market for the projected period of eight years. The primary objective of the report is to offer insights into developments in the global Crohns disease market that are affecting global businesses and enterprises. The report provides updates on market opportunities and insights to understand the growth and performance of the key segments of the global Crohns disease market. Through extensive research, Persistence Market Research analysts have studied how the different market dynamics are likely to impact the current and future scenario of the global Crohns disease market, thereby providing useful insights to market players to plan their future business strategies. The report covers the global Crohns disease market performance in terms of revenue contribution from various segments. This report also includes Persistence Market Researchs exclusive analysis of key trends, drivers, restraints and opportunities, which are influencing the growth of the global Crohns disease market. Impact analysis of key growth drivers and restraints are included in this report to better equip clients with crystal clear decision-making insights.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1293559

Report description

The report on the global Crohns disease market begins with an overview of Crohns disease, types of drugs used for treatment and key market definitions. The analysts also present an executive summary along with market taxonomy where the global Crohns disease market is segmented on the basis of drug type, distribution channel and region. The analysts also offer an unbiased analysis of overall market approach, target geographies and different strategies adopted by the key players across the globe to strengthen their market position in the next few years. Another section of the report consists of Crohns disease epidemiology, treatment paradigms and medications for the disease. The value chain of the market included in this report adds focus towards enhancing patient safety and product innovation that are key features expected to emerge in the global Crohns disease market.

The report concludes with a study of the market performance of some of the top companies operating in the global Crohns disease market. Persistence Market Research analysts have profiled some of the leading market players and presented a detailed analysis of their overall business performance and a comprehensive evaluation of their short-term and long-term business and go-to-market strategies. This section is intended to provide report audiences with a dashboard view of the competitive landscape of the global Crohns disease market.

Market segmentation

By Drug Type
- Anti-inflammatory drugs
- Immune system suppressors
- Antibiotics
- Biologics
- Anti-diarrheal
- Pain relievers

By Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores

By Region

- North America
- Latin America
- Europe
- Asia Pacific
- MEA

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-market-study-on-crohns-disease-anti-inflammatory-drugs-segment-anticipated-to-be-the-most-lucrative-segment-through-2024-report.html/toc

Exclusive research methodology

Yearly change in inflation rate has not been factored in while forecasting market numbers. While researching this report indicators such as R&D expenditure, research funding from government and non-profit organizations etc. have been considered to arrive at the indicated market numbers. A bottom-up approach has been used to evaluate market numbers for each product category, while top-down approach has been used to counter-validate the reached numbers. The analysts have done in-depth secondary research to ascertain overall market size, top industry players, and top products. In order to conduct expert and industry interviews, Persistence Market Research has formulated a detailed discussion guide, post which the analysts have conducted interviews with industry experts, industry players, retailers and distributors.

Market examination on Year-on-Year growth parameter

It is imperative to note that in an ever-fluctuating global economy, the report not only conducts forecasts in terms of CAGR but also analyzes the market on the basis of key parameters such as Year-on-Year (Y-o-Y) growth to understand the predictability of the market and to identify the right opportunities in the global Crohns disease market. Another key feature of this report is the analysis of the global Crohns disease market by region, drug type, by distribution channel and its revenue forecast in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global Crohns disease market. In order to understand key market segments in terms of growth and performance in the global Crohns disease market, Persistence Market Research has developed a market attractiveness index to help providers identify real market opportunities.

Company Profiles

- Allergan, Inc.,
- UCB S.A.
- AbbVie Inc.
- Perrigo Company plc
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Bayer AG
- Ferring B.V.
- Others

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=1293559

Global Parkinsons Disease Market Key Trends, Size, Growth, Shares And Forecast Research Report 2016 | Researchmoz

Researchmoz added Most up-to-date research on "Global Parkinsons Disease Market Report: 2016 Edition" to its huge collection of research reports.

Parkinsons Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinsons primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=715352

The current treatment market for Parkinsons disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinsons disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinsons along with possibility of developing “Stem Cell” as a treatment therapy.

The Parkinsons disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinsons disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.

The report, “Global Parkinsons disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-parkinsons-disease-market-report-2016-edition-report.html/toc

Table of Content

1. Market Overview1.1 Introduction   
1.2 Fundamental Features   
1.3 Types of Parkinson’s Disease   
1.4 Risk Factors   
1.5 Treatment Options

2. Global Market
2.1 Global Parkinson’s Disease Drug Market by Value   
2.1.1 Global Parkinson’s Disease Drug Market by Region   
2.1.2 Global Parkinson’s Disease Market by Drug Class   
2.1.3 Global Parkinson’s Disease Patient Population by Severity   
2.1.4 Global Parkinson’s Disease Patient Population by Region

3. Regional Markets
3.1 The U.S.   
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume   
3.1.2 The U.S. Parkinson’s Disease Market Value by Category   
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category   
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class   
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market   
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market   
3.2 The European Union   
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
3.2.2 The European Parkinson’s Disease Drug Market by Value   
3.3 Japan   
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure   
4.1.2 Rising Life Expectancy   
4.1.3 Rising Male Population   
4.1.4 Increasing Ageing Population   
4.1.5 Global Healthcare Expenditure   
4.1.6 Pesticides Consumption
4.2 Trends
4.2.1 Late-Stage Drug Development for Parkinson’s Disease   
4.2.2 Stem-Cell Therapy as Potential Treatment   
4.2.3 Biologics under Development for Parkinson’s Disease
4.3 Challenges
4.3.1 Generic Erosion   
4.3.2 Parkinson’s Treatment associated with Higher Risk of Melanoma   
4.3.3 Current Treatment Limitation

5. Competitive Landscape
5.1 The U.S. Parkinson’s Disease Branded Drug Market by Company   
5.2 The U.S. Parkinson’s Disease Generic Drug Market by Company

Continue...

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=715352

Recent Survey | The US Home Dialysis Market: Size, Trends & Forecasts (2017-2021) - Fresenius Medical Care, DaVita, U.S. Renal Care, Dialysis Clinic Inc.

Researchmoz added Most up-to-date research on "The US Home Dialysis Market: Size, Trends & Forecasts (2017-2021)" to its huge collection of research reports.

The report titled The US Home Dialysis Market: Size, Trends & Forecasts (2017-2021) highlights an in-depth analysis of market sizing and growth of the US Home Dialysis Market. The analysis includes market size in terms of value as well as volume and market share by segments.

Furthermore, the report also assesses the key opportunities available in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the US home dialysis market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The competition in the US home dialysis market is stiff and majority of market share is dominated by few major players such as Fresenius Medical Care, DaVita, U.S. Renal Care and, Dialysis Clinic Inc. whose company profiling has been done in the report, which include their business overview, financial overview and respective business strategies.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1358877

Company Coverage

Fresenius Medical Care
DaVita
U.S. Renal Care
Dialysis Clinic Inc.

Executive Summary

The process of purifying blood by eliminating waste materials and excessive fluid from the body in case, the kidneys of the human body is not function properly is known as dialysis. In the dialysis process blood is filtered and purified with the help of technological advanced machinery. The treatment has been used since 1940s to treat patients suffering from chronic kidney diseases. It is the most widely accepted treatment for end stage renal diseases and kidney failures. The primary objective of dialysis process is to help damaged renal function. The three major types of dialysis are: Hemodialysis (HD), Peritoneal Dialysis (PD) and, Home Hemodialysis (HHD).

A home dialysis is either hemodialysis or peritoneal dialysis which can perform at home with the help of advanced machinery. A skilled clinical person can teach a person how to perform dialysis at home. Home dialysis has been recognized by patients and physicians as a safe and effective alternative to in-center treatment. Home dialysis is broadly classified into four categories: Daily home Hemodialysis (HD), Nocturnal Home hemodialysis, Nocturnal In-Center hemodialysis, Standard Home hemodialysis.

The US Home Dialysis market, both in terms of value as well as volume has increased over the past few years and projections are made that the market would grow further at a rapid pace in the forecasted period i.e. 2017-2021 also. The US home dialysis market is expected to grow on the back of aging US population, growing kidney chronic diseases, rising life expectancy of dialysis patients, convenience over in-traditional dialysis centers, technological advancements such as trend toward using sorbent technology to allow online regeneration for dialysate to facilitate portability, etc. Yet the growth of the market is obstructed by factors such as technical issues, lack of substantial housing and legal and financial requirements.

Table Of Content

1. Executive Summary

2. Introduction
2.1 Overview of Dialysis
2.1.1 Types of Dialysis
2.2 Overview of Home Dialysis
2.2.1 Types of Home Dialysis
2.2.2 Home Treatments Comparison: Positives and Negatives

3. The US Market Analysis

3.1 The US Dialysis Market Analysis
3.1.1 The US Dialysis Market by Volume
3.1.2 The US Dialysis Market by Segments

3.2 The US Home Dialysis Market Analysis
3.2.1 The US Home Dialysis Market by Volume
3.2.2 The US Home Dialysis Market by Value

4. Market Dynamics

4.1 Growth Drivers
4.1.1 Aging Population
4.1.2 Growing Chronic Kidney Disease
4.1.3 Rising Life Expectancy of Dialysis Patient
4.1.4 Great Deal of Convenience over Traditional In-Center
4.1.5 Rising Healthcare Expenditure

4.2 Challenges
4.2.1 Technical Issues
4.2.2 Lack of Suitable Housing
4.2.3 Legal and Financial Requirements
4.3 Market Trends
4.3.1 Technological Advancements
4.3.2 Prospective Payment System

5. Competitive Landscape
5.1 The US Home Dialysis Market Players Comparison by Products
5.2 The US Home Dialysis Market Players by Number of Patients

6. Company Profiling

6.1 Fresenius Medical Care
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 DaVita
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 U.S. Renal Care
6.3.1 Business Overview
6.3.2 Business Strategy

6.4 Dialysis Clinic Inc.
6.4.1 Business Overview
6.4.2 Business Strategy

Browse Detail Report With TOC @ https://www.researchmoz.us/the-us-home-dialysis-market-size-trends-and-forecasts-2017-2021-report.html

Global Anticoagulant Market To Grow At A CAGR Of 7.42% During The Period 2017-2021 Key vendors - Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Sanofi

Researchmoz added Most up-to-date research on "Global Anticoagulant Market 2017-2021" to its huge collection of research reports.

Anticoagulant prevent clot formations or the enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists; DTIs; and factor Xa inhibitors are among the anticoagulant that are available in the market. They are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi are some of the top vendors in the market.

Technavios analysts forecast the global anticoagulant market to grow at a CAGR of 7.42% during the period 2017-2021.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1027767

Covered in this report
The report covers the present scenario and the growth prospects of the global anticoagulant market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders.

The market is divided into the following segments based on geography:
Americas
EMEA
APAC

Global Anticoagulant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Bayer HealthCare
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Johnson & Johnson
Sanofi

Browse Detail Report With Full TOC @ https://www.researchmoz.us/global-anticoagulant-market-2017-2021-report.html

Other prominent vendors
Abbott Vascular
Abiomed
AtriCure
Biosensors International
Biotronik
BioVentrix
C. R. Bard

Market driver
Increasing demand for NOACs
For a full, detailed list, view our report

Market challenge
Increasing cost of NOACs
For a full, detailed list, view our report

Market trend
Strategic alliance
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=1027767

Global Orphan Drugs Market To Grow At A CAGR Of 10.20% During The Period 2017-2021 Key vendors – AbbVie, Celgene, F. Hoffmann La Roche, Novartis

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market 2017-2021" to its huge collection of research reports.

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.


To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1059719

Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Celgene
F. Hoffmann La Roche
Novartis

Browse Detail Report With Full TOC @ https://www.researchmoz.us/global-orphan-drugs-market-2017-2021-report.html

Other prominent vendors
Amgen
Actelion
Alexion Pharmaceuticals
Bayer
Biogen
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Novo Nordisk
Pfizer
Sanofi
Shire
Teva pharmaceutical

Market driver
Large growth opportunities through orphan drug designation.
For a full, detailed list, view our report

Market challenge
Costly treatment regimen results in financial burden on patients.
For a full, detailed list, view our report

Market trend
Emerging application for orphan drug development.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1059719

Global Anticoagulant Market To Grow At A CAGR Of 7.42% During The Period 2017-2021 Key Vendors - Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Sanofi

Researchmoz added Most up-to-date research on "Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021)" to its huge collection of research reports.

The report entitled Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by treatment, by segment, and by products.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1068332

The report also provides analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales.

A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.

Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.

Company Coverage

Bayer Group
BMS/Pfizer
Boehringher Ingelheim
Daiichi Sankyo

Country Coverage

The US

Executive Summary

Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.

The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.

The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2017-2021, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.

Major Points in Talble Of Content

1. Executive Summary

2. Introduction
2.1 Overview of Anticoagulants
2.1.1 Types of Anticoagulants
2.1.2 Novel Oral Anticoagulants

3. Global Market Analysis

3.1 Global Anticoagulants Market Analysis
3.1.1 Global Anticoagulants Market by Value
3.1.2 Global Anticoagulants Market Share by Treatment
3.1.3 Global Anticoagulants Market Share by Segment
3.1.4 Global Anticoagulants Market Share by Products

4. Global Anticoagulants Product Analysis

4.1 Injectable Anticoagulants Product Analysis
4.1.1 Global Lovenox Market by Value
4.1.2 Global Arixtra Market by Value
4.2 Oral Anticoagulants Product Analysis
4.2.1 Global Xarelto Market by Value 27
4.2.2 Global Eliquis Market by Value 28
4.2.3 Global Pradaxa Market by Value 29
4.2.4 Global Savaysa Market by Value 30

5. Region/Country Analysis

5.1 The US Anticoagulants Market Analysis
5.1.1 The US Anticoagulants Market by Value
5.1.2 The US Xarelto Market by Value
5.1.3 The US Eliquis Market by Value
5.1.4 The US Pradaxa Market by Value
5.1.5 The US Savaysa Market by Value

6. Market Dynamics

6.1 Growth Drivers

6.1.1 Growing Aging Population
6.1.2 Rising Prevalence of Coagulation Disorder
6.1.3 Increasing Demand for NOACs
6.1.4 Rising Awareness about Anticoagulants
6.1.5 Pressure to Curtail Spending on Healthcare
6.1.6 Increasing Incidence of Atrial Fibrillation

6.2 Challenges

6.2.1 High Cost Of NOACs
6.2.2 Lack of Antidotes for NOACs
6.2.3 Strict Regulations
6.2.4 Side Effects Associated with Drugs

6.3 Market Trends

6.3.1 Strategic Alliance
6.3.2 Expanding Therapeutic Applications
6.3.3 Patient Assistance Programs

7. Competitive Landscape

7.1 Global Top Oral Anticoagulants by Sales
7.2 Global Anticoagulants Market Players by Product Comparison

8. Company Profiling

8.1 Bayer Group

8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy

8.2 BMS/Pfizer

8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy

8.3 Boehringher Ingelheim

8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy

8.4 Daiichi Sankyo

8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1068332

Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD

Researchmoz added Most up-to-date research on "Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression" to its huge collection of research reports.

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1135804

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Scope

Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden

- What are the most important etiological risk factors and pathophysiological processes implicated in AD?
- What is the current treatment algorithm?
- How common are anxiety, depression, psychosis and insomnia in AD?

The AD pipeline is large and contains a very high proportion of first-in-class product innovation

- Which molecule types and molecular targets are most prominent across AD and its associated indications?
- What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
- How does first-in-class target diversity differ by stage of development and molecular target class?

The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products

- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1135804

New Study Reveals Global Peripheral Artery Disease Market Report 2016 | Researchmoz

Researchmoz added Most up-to-date research on "Global Peripheral Artery Disease Market Report: 2016 Edition" to its huge collection of research reports.

Peripheral Artery Disease (PAD) is a medical condition in which plaque builds up on the artery walls, blocking the flow of oxygen-rich blood to the legs, stomach, and arms. Major factors causing PAD are smoking, diabetes, high blood pressure, abnormal cholesterol levels, advancing age and a personal history of vascular disease. The earliest symptom of Peripheral Artery Disease is a cramp-like muscular discomfort called intermittent claudication, while numbness, tingling, weakness or fatigue is also experienced. Patients with severe PAD often develop ulcers in their legs and feet. Its prevention involves a lifelong program involving certain lifestyle changes like healthy eating and physical exercise.

Medical Diagnosis of PAD includes methods like Ankle-Brachial Index, Ultrasound, Angiography, Catheter Angiography and Blood Tests. There are a number of treatment options for the disease that can be used alone or mixed with other devices. They are Percutaneous Trans Luminal Angioplasty (PTA), Drug-Coated Balloons, Stents, Drug-Eluting Stents, Arterial Bypass and Atherectomy.

The global peripheral artery disease market, bolstered by rising healthcare expenditures has seen a persistent growth in the last few years. The report provides an overview of the entire global peripheral artery disease market including the devices market and the atherectomy market. Certain key trends like increased used of DCBs and favorable reimbursements have also been discussed. Growth drivers including rising ageing population, obesity and healthcare expenditures find mention in the report along with the challenges and limitations including underpenetrated treatment market for PAD.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=712498

Competition in the global peripheral artery disease market is rather fragmented with big companies recording excellent profits while smaller companies continue to gain prevalence through research and innovation.

The report has forecasted future trend in the global Peripheral Artery Disease market by combining SPSS Inc.’s data integration and analysis capabilities. Regression models have been created by employing various significant variables that have an impact on the market. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables, and tests.

Table of Content

1. Market Overview 1.1 Introduction
1.2 Causes of Peripheral Artery Disease
1.3 Prevention
1.4 Diagnosis
1.4.1 Symptoms
1.4.2 Medical Diagnosis
1.5 Treatment Options for Peripheral Artery Disease
1.5.1 Percutaneous Trans Luminal Angioplasty (PTA)
1.5.2 Drug-Coated Balloons (DCBs)
1.5.3 Stents
1.5.4 Drug-Eluting Stents (DES)
1.5.5 Arterial Bypass
1.5.6 Atherectomy

2. Global Peripheral Artery Disease Market
2.1 Global Peripheral Artery Disease Market by Value
2.2 Global Peripheral Artery Disease Prevalence
2.3 Global Peripheral Artery Devices Market
2.3.1 Peripheral Artery Devices Market by Treatment
2.3.2 Drug Eluting Stents Market by Volume
2.3.3 Drug Eluting Stents Market by Geography

3. Regional Peripheral Artery Disease Market
3.1 The U.S.
3.1.1 The U.S. PAD Diagnosed Cases
3.1.2 The U.S. PAD Interventions and Penetration
3.1.3 The U.S. DCB Procedures and Penetration
3.1.4 The U.S. DCB Market by Value
3.1.5 The U.S. Stents/PTA Procedures and Penetration
3.2 The European Union
3.2.1 The EU PAD Diagnosed cases
3.2.2 The EU PAD Intervention and Penetration

4. Peripheral Atherectomy Market
4.1 Global Peripheral Atherectomy Market
4.2 Regional Peripheral Atherectomy Market
4.2.1 The U.S. Peripheral Atherectomy Market by Value
4.2.2 The European Union Peripheral Atherectomy Market by Value

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Ageing Population
5.1.2 Rising Proportion of Health Expenditure in Emerging Economies
5.1.3 Increasing Obese Population
5.1.4 Rise of Drug-Coated Balloons in the US
5.1.5 Escalating Healthcare Spending
5.2 Trends
5.2.1 DCBs Spur Growth of Atherectomy Market
5.2.2 DCB the Preferred Treatment for ISR
5.2.3 Favorable Atherectomy Reimbursements
5.3 Challenges
5.3.1 PAD market is underpenetrated
5.3.2 PAD Devices to be Hurt by DCBs
5.3.3 Limitation of Peripheral Interventions

6. Competitive Landscape
6.1 Global Peripheral Artery Disease Market by Company
6.2 Global Peripheral Atherectomy Market by Company
6.3 The US Peripheral Atherectomy Market Share

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=712498

Global Parkinsons Disease Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2016

Researchmoz added Most up-to-date research on "Global Parkinsons Disease Market Report: 2016 Edition" to its huge collection of research reports.

Parkinsons Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinsons primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.

The current treatment market for Parkinsons disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinsons disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinsons along with possibility of developing “Stem Cell” as a treatment therapy.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=715352

The Parkinsons disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinsons disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.

The report, “Global Parkinsons disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Content

1. Market Overview1.1 Introduction   
1.2 Fundamental Features   
1.3 Types of Parkinson’s Disease   
1.4 Risk Factors   
1.5 Treatment Options

2. Global Market
2.1 Global Parkinson’s Disease Drug Market by Value   
2.1.1 Global Parkinson’s Disease Drug Market by Region   
2.1.2 Global Parkinson’s Disease Market by Drug Class   
2.1.3 Global Parkinson’s Disease Patient Population by Severity   
2.1.4 Global Parkinson’s Disease Patient Population by Region

3. Regional Markets
3.1 The U.S.   
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume   
3.1.2 The U.S. Parkinson’s Disease Market Value by Category   
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category   
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class   
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market   
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market   
3.2 The European Union   
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
3.2.2 The European Parkinson’s Disease Drug Market by Value   
3.3 Japan   
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure   
4.1.2 Rising Life Expectancy   
4.1.3 Rising Male Population   
4.1.4 Increasing Ageing Population   
4.1.5 Global Healthcare Expenditure   
4.1.6 Pesticides Consumption
4.2 Trends
4.2.1 Late-Stage Drug Development for Parkinson’s Disease   
4.2.2 Stem-Cell Therapy as Potential Treatment   
4.2.3 Biologics under Development for Parkinson’s Disease
4.3 Challenges
4.3.1 Generic Erosion   
4.3.2 Parkinson’s Treatment associated with Higher Risk of Melanoma   
4.3.3 Current Treatment Limitation

5. Competitive Landscape
5.1 The U.S. Parkinson’s Disease Branded Drug Market by Company   
5.2 The U.S. Parkinson’s Disease Generic Drug Market by Company

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=715352

Latest Study Reveals Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Researchmoz added Most up-to-date research on "Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products" to its huge collection of research reports.

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure, and is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the patent’s history of alcohol use.

FLD is the most common chronic liver disease in the world, and its global prevalence has increased rapidly in the past several decades. The worldwide prevalence of FLD is estimated at 20–45% in the general population, and up to 90% in obese patients. There is a broad consensus to describe the condition as the hepatic manifestation of metabolic syndrome, and it is closely associated with obesity, diabetes and dyslipidemia. NAFLD has become the main driver of the rapid growth of FLD prevalence, mainly due to the rising prevalence of obesity.

FLD is increasingly recognized as a major global health problem. However, despite this the FLD market is still in its infancy, with no FDA-approved drugs for this indication, and only a limited number of generic drugs approved in non-US markets in recent years.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1065937

Due to the increasing health burden of FLD and the lack of therapeutic options, there is a pressing need to develop pharmacological strategies. This is especially the case for patients with steatohepatitis, who are at the greatest risk of developing cirrhosis or liver cancer, which can lead to liver failure. Due to the pathophysiological complexity of FLD and its diverse population, different therapeutic agents are likely to be needed to tackle the lipotoxicity, inflammation and fibrogenesis that drive FLD progression.

FLD has an active pipeline and first-in-class products account for a considerable proportion, which is very promising considering the level of unmet need and lack of approved treatment options. First-in-class innovation is concentrated heavily at the early drug development stages, and prominent first-in-class molecular targets include nuclear receptors, immune mediators, and molecules involved in lipid synthesis. Additionally, the first-in-class targets identified show considerable diversity, reflecting the multifaceted aspects of FLD pathophysiology.

Scope

FLD comprises a diverse patient population with significant unmet needs
-  What is the pathophysiology of FLD?
-  What are the common co-morbidities and complications?
-  What are the most significant unmet needs within the market?

The FLD pipeline is relatively large and has a high degree of first-in-class innovation
-  Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The FLD deal landscape shows rising deal volumes and considerable investment opportunities

- Do FLD products attract high deal values?
- Which molecule types and molecular targets dominate the deals landscape?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.
- Visualize the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to FLD, all first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1065937

Global Wilsons Disease Market: Industry Analysis & Outlook (2016-2020) | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Global Wilsons Disease Market: Industry Analysis & Outlook (2016-2020)" to its huge collection of research reports.

Wilson’s disease is a rare disease and is named after Kinnear Wilson who was the first to describe this disorder in 1912. His description terms the disease as a “progressive lenticular degeneration,” a hereditary, fatal neurological disease that is usually accompanied by chronic liver ailment that leads to a condition called cirrhosis. Wilson's disease is a hereditary disorder that leads to unwarranted accumulation of copper in crucial organs such as the liver, brain etc. The patient starts to accumulate copper from birth but diagnosis tends not to occur only in the later ages. The primary signs of Wilson’s disease become prominent usually between the ages of 12 and 23 years.

Wilson’s disease is caused by the mutation of a gene named ATP7B. Absent or reduced function of ATP7B protein leads to reduced elimination of copper into the bile. Wilson’s disease is inherited as an autosomal recessive trait, which means that in order to develop the disease one must inherit two procreations of the defective gene, one from each parent. If a person receives only one abnormal gene from either of the parents, he/she is not likely to get affected by the Wilson’s disease. Wilson’s disease may be difficult to primarily diagnose as the symptoms are alike to other health issues like heavy metal poisoning, hepatitis C, and cerebral palsy.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=795721

The important factors that are anticipated to drive the market include rising prices of chelators in the US, rising attractiveness of orphan drugs market, increasing global healthcare expenditure as well as spending on medicines. The noteworthy trends in the market include falling number of prescriptions for Wilson’s disease, and the development of gene therapy as a potential cure for the disease. However, the market is confronted by crucial challenges such as under-diagnosis of the disease, lack of safety in treatments, poor compliance to current treatments and unmet efficacy needs.

This report provides a wide-ranging study of global Wilson’s disease market and also its key regional markets such as the US and Europe. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global Wilson’s disease industry is highly competitive consisting of several large corporations. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Content

1. Market Overview1.1 Introduction   
1.2 Causes   
1.3 Symptoms   
1.3.1 Hepatic Symptoms   
1.3.2 Neurological Symptoms   
1.3.3 Ophthalmic Symptoms   
1.3.4 Other Symptoms   
1.4 Diagnosis   
1.5 Treatment through Medications   
1.5.1 D-penicillamine   
1.5.2 Trientine   
1.5.3 Zinc Salts   
1.5.4 Ammonium tetrathiomolybdate   
1.5.5 Bis-Choline Tetrathiomolybdate – Decuprate

2. Global Market
2.1 Global Orphan Drugs Market Revenue – Actuals   
2.2 Global Orphan Drugs Market Revenue – Forecast   
2.3 Wilson’s Disease Prevalence by Region   
2.4 Wilson’s Disease Market by Treatment – New Patients   
2.5 Wilson’s Disease Market by Treatment – Experienced Patients   
2.6 Global Decuprate Revenue – Forecast   
2.7 Global Liver Transplantation by Region

3. Regional Markets
3.1 Europe   
3.1.1 Wilson’s Disease Prevalence – Forecast   
3.1.2 Wilson’s Disease Market by Treatment   
3.1.3 Wilson’s Disease Patients Treated with Zinc – Forecast   
3.1.4 Wilson’s Disease Patients Treated with Chelators – Forecast   
3.1.5 Wilson’s Disease Patients Treated with Decuprate – Forecast
3.2 The US   
3.2.1 Wilson’s Disease Prevalence – Forecast   
3.2.2 Wilson’s Disease Market by Treatment   
3.2.3 Wilson’s Disease Patients Treated with Zinc – Forecast   
3.2.4 Wilson’s Disease Patients Treated with Chelators – Forecast   
3.2.5 Chelators Market Revenue – Actuals   
3.2.6 Chelators Market Revenue – Forecast   
3.2.7 Wilson’s Disease Patient Treated with Decuprate – Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Prices of Chelators in the US
4.1.2 Rising Attractiveness of Orphan Drug Market   
4.1.3 Rising Global Spending on Medicines   
4.1.4 Increasing Healthcare Expenditure
4.2 Trends
4.2.1 Falling Number of Prescription for Chelators   
4.2.2 Gene Therapy for Wilson’s Disease
4.3 Challenges
4.3.1 Under-Diagnosis of the Disease   
4.3.2 Lack of Safety in Treatments   
4.3.3 Poor Compliance of Patients to Current Treatments   
4.3.4 Unmet Efficacy Needs

5. Competitive Landscape
5.1 Competition by Revenue   
5.2 Competition by Market Capitalization   
5.3 Competition by Profitability

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=795721

Global Orphan Drugs Market To Grow At A CAGR Of 10.20% During The Period 2017-2021

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market 2017-2021" to its huge collection of research reports.

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1059719

Technavio's report, Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Celgene
F. Hoffmann La Roche
Novartis

Other prominent vendors
Amgen
Actelion
Alexion Pharmaceuticals
Bayer
Biogen
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Novo Nordisk
Pfizer
Sanofi
Shire
Teva pharmaceutical

Market driver
Large growth opportunities through orphan drug designation.
For a full, detailed list, view our report

Market challenge
Costly treatment regimen results in financial burden on patients.
For a full, detailed list, view our report

Market trend
Emerging application for orphan drug development.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1059719

Global Alopecia Drugs Industry Will Grow Steadily At A CAGR Of 5.02% During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Alopecia Drugs Market 2016-2020" to its huge collection of research reports.

Alopecia is a loss of hair and can occur at any age across the genders. The exact cause of this disorder is unknown, but many factors are assumed to be responsible for developing alopecia. Few of the primary ones are a sedentary lifestyle, unhealthy diets, and side effects of certain medical treatments. Moreover, hormonal imbalance and aging increase the probability of developing a chronic disease like cancer, arthritis, depression, and hypertension, which would also lead to hair loss, especially among middle-to-late-aged people.

Technavios analysts forecast the global alopecia drugs market to grow at a CAGR of 5.02% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global alopecia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of alopecia drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=877700

Technavio's report, Global Alopecia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline
Johnson & Johnson
Merck

Other prominent vendors
Aclaris Therapeutics
Actelion Pharmaceuticals
Almirall
AndroScience
Anterios
Aqua Pharmaceuticals
Astellas Pharma
Bayer HealthCare
BERG Health
BiologicsMD
BioPharmX
Celtaxsys
Cipher Pharmaceuticals
Concert Pharmaceuticals
Cosmo Pharmaceuticals
Dermira
Elorac
F. Hoffmann-La Roche
Foamix
Guthy-Renker
Helix BioMedix
Hygeia Therapeutics
Hyundai Pharm
Incyte
Kasiak Research
Kythera Biopharmaceuticals
Mylan
NovaLead Pharma
Novan
Oculus Innovative Sciences
Paratek Pharmaceuticals
Photocure
Polichem
Promius Pharma
Ranbaxy Laboratories
Reckitt Benckiser
Regience
Samumed
RepliCel
Skinvisible Pharmaceuticals
Teva Pharmaceutical
Versapharm
XBiotech

Market driver
Popularity of off-label and OTC drugs
For a full, detailed list, view our report

Market challenge
Limited availability of approved drugs
For a full, detailed list, view our report

Market trend
Emergence of laser technology and platelet-rich plasma (PRP) therapy
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=877700